BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
Zacks·2d ago
More News
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
Zacks·9d ago
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
Zacks·15d ago
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Here is how Medpace (MEDP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Zacks·15d ago
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·17d ago
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
Zacks·28d ago
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Zacks·1mo ago
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
Zacks·1mo ago
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
Zacks·1mo ago
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.